Compare Cadila Healthcare with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs ASTRAZENECA PHARMA - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE ASTRAZENECA PHARMA CADILA HEALTHCARE/
ASTRAZENECA PHARMA
 
P/E (TTM) x 29.4 116.0 25.4% View Chart
P/BV x 3.5 33.9 10.4% View Chart
Dividend Yield % 1.0 0.0 -  

Financials

 CADILA HEALTHCARE   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-19
ASTRAZENECA PHARMA
Mar-18
CADILA HEALTHCARE/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs4321,278 33.8%   
Low Rs306883 34.7%   
Sales per share (Unadj.) Rs128.6228.4 56.3%  
Earnings per share (Unadj.) Rs18.510.4 179.0%  
Cash flow per share (Unadj.) Rs24.416.3 150.0%  
Dividends per share (Unadj.) Rs3.500-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs101.598.8 102.7%  
Shares outstanding (eoy) m1,023.7425.00 4,095.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.94.7 60.7%   
Avg P/E ratio x19.9104.2 19.1%  
P/CF ratio (eoy) x15.166.4 22.8%  
Price / Book Value ratio x3.610.9 33.3%  
Dividend payout %18.90-   
Avg Mkt Cap Rs m378,17027,008 1,400.2%   
No. of employees `00012.41.4 917.3%   
Total wages/salary Rs m21,2411,535 1,383.5%   
Avg. sales/employee Rs Th10,585.04,210.9 251.4%   
Avg. wages/employee Rs Th1,707.81,132.2 150.8%   
Avg. net profit/employee Rs Th1,526.5191.1 798.9%   
INCOME DATA
Net Sales Rs m131,6565,710 2,305.7%  
Other income Rs m2,011123 1,641.6%   
Total revenues Rs m133,6675,833 2,291.8%   
Gross profit Rs m29,731463 6,422.8%  
Depreciation Rs m5,986147 4,061.1%   
Interest Rs m1,9350-   
Profit before tax Rs m23,821438 5,438.6%   
Minority Interest Rs m4690-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,303179 2,964.2%   
Profit after tax Rs m18,987259 7,328.1%  
Gross profit margin %22.68.1 278.6%  
Effective tax rate %22.340.8 54.5%   
Net profit margin %14.44.5 317.8%  
BALANCE SHEET DATA
Current assets Rs m84,9813,209 2,648.0%   
Current liabilities Rs m73,4252,070 3,548.0%   
Net working cap to sales %8.820.0 44.0%  
Current ratio x1.21.6 74.6%  
Inventory Days Days7572 103.0%  
Debtors Days Days11035 313.7%  
Net fixed assets Rs m133,493790 16,891.4%   
Share capital Rs m1,02450 2,048.0%   
"Free" reserves Rs m102,8392,419 4,250.8%   
Net worth Rs m103,8632,469 4,206.2%   
Long term debt Rs m39,4970-   
Total assets Rs m234,8314,605 5,099.0%  
Interest coverage x13.3NM-  
Debt to equity ratio x0.40-  
Sales to assets ratio x0.61.2 45.2%   
Return on assets %8.95.6 158.4%  
Return on equity %18.310.5 174.2%  
Return on capital %18.317.7 103.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m48,404300 16,158.9%   
Fx outflow Rs m11,5932,015 575.4%   
Net fx Rs m36,811-1,715 -2,146.0%   
CASH FLOW
From Operations Rs m28,82388 32,790.7%  
From Investments Rs m-57,387-94 61,310.9%  
From Financial Activity Rs m18,846NA-  
Net Cashflow Rs m-7,105-6 124,649.1%  

Share Holding

Indian Promoters % 74.8 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 8.3 0.3 2,766.7%  
FIIs % 5.9 15.7 37.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 9.1 120.9%  
Shareholders   44,069 12,856 342.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   STERLING BIOTECH  SANOFI INDIA  ALEMBIC PHARMA  PROCTER & GAMBLE HEALTH  NOVARTIS  

Compare CADILA HEALTHCARE With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slips Over 550 Points; Nifty Falls Below 10,700 Mark(11:30 am)

Share markets in India have extended early losses and are presently trading deep in the red.Benchmark indices edged lower today tracking weak Asian markets.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

These 3 Recent Events Will Impact the Price of Gold(Fast Profits Daily)

Jul 1, 2020

Recent developments in the bullion market may put some short term pressure on gold prices.

Smallcaps Are in a Sweet Spot Again: Are You Buying?(Profit Hunter)

Jul 3, 2020

This is why I believe smallcaps are the place to be in the near future.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Jul 14, 2020 12:07 PM

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS